Gavin Brittain, Jennifer Petrie, Kate E M Duffy, Rachel Glover, Katie Hullock, Diana Papaioannou, Elisa Roldan, Colette Beecher, Matthew Bursnall, Olga Ciccarelli, Alasdair J Coles, Cindy Cooper, Gavin Giovannoni, Ian Gabriel, Majid Kazmi, Charalampia Kyriakou, Richard Nicholas, David Paling, Andy Peniket, Neil Scolding, Eli Silber, Thushan de Silva, Annalena Venneri, Stephen J Walters, Carolyn Young, Paolo A Muraro, Basil Sharrack, John A Snowden
INTRODUCTION: Autologous haematopoietic stem cell transplantation (aHSCT) is increasingly used as treatment for patients with active multiple sclerosis (MS), typically after failure of disease-modifying therapies (DMTs). A recent phase III trial, 'Multiple Sclerosis International Stem Cell Transplant, MIST', showed that aHSCT resulted in prolonged time to disability progression compared with DMTs in patients with relapsing remitting MS (RRMS). However, the MIST trial did not include many of the current high-efficacy DMTs (alemtuzumab, ocrelizumab, ofatumumab or cladribine) in use in the UK within the control arm, which are now offered to patients with rapidly evolving severe MS (RES-MS) who are treatment naïve...
February 5, 2024: BMJ Open